Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Pluri Inc PLUR

Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. It develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. The company’s product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to coronavirus Disease (COVID-19), peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and is in Phase I clinical trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform. It ...


NDAQ:PLUR - Post by User

<< Previous
Bullboard Posts
Next >>
Post by lucaM1on Apr 24, 2022 9:58am
147 Views
Post# 34627149

Israeli Companies Want to Bring Lab-grown Meat to the Masses

Israeli Companies Want to Bring Lab-grown Meat to the Masses

An Israeli biotech company and food giant Tnuva rang the bell at NASDAQ March 28, celebrating their partnership to produce lab-grown meat.

Pluristem Therapeutics and Tnuva joined the race to create meat products from animal cells, using technology they say is more sustainable than natural methods and hoping to meet the demand for cruelty-free alternatives.

Tnuva is investing $7.5 million in the partnership, called NewCo, with an option to invest up to an additional $7.5 million over a year-long period.

Pluristem CEO Yaky Yanay called the initial product “cultured meat” and said it is grown from real meat cells, tissue, fat and muscle. “We’re not talking about a substitute,” Yanay told the New York Jewish Week. “We will be able to provide a product that will be healthy and eventually affordable.”


https://jmoreliving.com/2022/04/22/israeli-companies-want-to-bring-lab-grown-meat-to-the-masses/
<< Previous
Bullboard Posts
Next >>